3 active not recruiting, 2 completed, 1 terminated. 6 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 3, Completed 2, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
Follow varlilumab: new trials by email Literature Review of varlilumab trials Research Report on varlilumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer Atezolizumab, Biopsy, Biospecimen Collection - Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 57 | 2021-12-15 | 2025-05-23 |
| DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab Human CMV pp65-LAMP mRNA-pulsed autologous DCs, Temozolomide, Varlilumab - Glioblastoma | Phase 2 | Active not recruiting | Annick Desjardins, MD | 43 | 2020-08-26 | 2026-05-22 |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Nivolumab, Varlilumab - ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2018-12-21 | 2026-10-26 |
| Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma 6MHP, Montanide ISA-51, polyICLC - Melanoma | Phase 1 / Phase 2 | Completed | Craig L Slingluff, Jr | 33 | 2018-11-13 | 2024-02-06 |
| A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma Varlilumab - B Cell Lymphoma | Phase 1 / Phase 2 | Completed | University Hospital Southampton NHS Foundation Trust | 26 | 2017-11-23 | 2024-12-02 |
| A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma glembatumumab vedotin, glembatumumab vedotin and varlilumab, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab) - Melanoma | Phase 2 | Terminated | Celldex Therapeutics | 132 | 2014-11-01 | 2019-09-06 |
Lymphoma, B-Cell (2) · Melanoma (2) · Burkitt Lymphoma (1) · Cholangiocarcinoma (1) · Gallbladder Neoplasms (1) · Glioblastoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Primary Effusion (1) · Lymphomatoid Granulomatosis (1) · Plasmablastic Lymphoma (1) · Skin Neoplasms (1)
National Cancer Institute (NCI) (2) · Annick Desjardins, MD (1) · Celldex Therapeutics (1) · Craig L Slingluff, Jr (1) · University Hospital Southampton NHS Foundation Trust (1)
United States (5) · United Kingdom (1)
Annick Desjardins, MD, FRCPC (1) · Craig L Slingluff, Jr., MD (1) · Nilofer S Azad (1) · Stephen M Ansell (1)
UM1CA186686 (1), UM1CA186691 (1), UM1CA186709 (1)